NanoViricides
NNVC

$1.56

6.02%

Market Cap: $18.4M

About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

67% more capital invested

Capital invested by funds: $1.38M [Q1] → $2.31M (+$926K) [Q2]

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

17% more funds holding

Funds holding: 29 [Q1] → 34 (+5) [Q2]

1.23% more ownership

Funds ownership: 10.14% [Q1] → 11.38% (+1.23%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NNVC.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about NNVC published over the past 30 days

Proactive Investors

NanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMI

NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral. Diwan explained that NV-387, a host mimetic drug, works differently from traditional antiviral treatments by mimicking a natural cellular feature, making it difficult for viruses to escape.

NanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMI

Proactive Investors

NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX

NanoViricides (NYSE-A:NNVC) announced that it is investigating the potential use of its lead drug candidate NV-387 to treat MPOX patients under the World Health Organization's Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol. This follows the organization's recent declaration of a Public Health Emergency due to the 2024 MPOX outbreak.

NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it is investigating the possibility of using NV-387 for the treatment of MPOX patients under the WHO MEURI protocol, in light of the recent WHO PHEIC (Public Health Emergency of International Concern) declaration for the current 2024 MPOX outbreak that is rapidly spreading into more than ten countries in Africa with additional cases detected in Thailand and Sweden. MEURI, i.e.

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Proactive Investors

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387

NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which has shown promise in treating various viral infections including RSV, COVID-19, and Influenza in animal studies, could revolutionize the treatment of respiratory viruses, according to the company.

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities. Dr. Anil Diwan, the Company's President, and Executive Chairman, is currently visiting with various expert professionals with the objective of developing a Phase II clinical trial plan and corresponding clinical protocol for a Phase II clinical trial of the drug candidate NV-387.

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Proactive Investors

NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387

NanoViricides (NYSE-A:NNVC) has highlighted significant progress made in advancing its lead drug candidate NV-387 during the 2024 fiscal year 2024, which ended June 30, in a letter to investors. NV-387 is designed to disable viruses by mimicking the host cell, targeting a wide range of viruses including Influenza, COVID, RSV, and more.

NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program and strategy in this letter to investors. NanoViricides is developing a unique direct-acting antiviral drug that mimics the host cell and thereby is designed to disable the virus particle from infecting the cell.

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and nanotechnology issues a snapshot looking at news and developments in the antiviral market, featuring NanoViricides, Inc. (NYSE American: NNVC), a development stage company that is creating special purpose nanomaterials for antiviral therapy. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/nanotech/08020Better-Solutions-for-Viruses.asp From COVID to RSV and now Bird Flu, the global threat of viruses is only a headline away and there is a lot of profit for companies offering solutions.

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Proactive Investors

NanoViricides' lead asset for broad spectrum efficacy wins praise in industry reports

NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential of its broad spectrum drug candidate NV-387 as a viral therapy. In a research note titled “NNVC: NanoViricides (NYSE-A:NNVC) Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy,” author Dr David Bautz of ZacksSCR described the antiviral asset NV-387 as “exciting.

NanoViricides' lead asset for broad spectrum efficacy wins praise in industry reports

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate and independent research reports have been published by industry analysts on the Company. "NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy," is the title of a new research note published by David Bautz, PhD, Zacks SCR, on July 31st, 2024.

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

See News Rankings